Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics, Inc. (SRPT) scores 31 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is 18.46, representing a 5% margin of safety. Quantitative score: 48/100. Qualitative score: 20/100.

Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.

View full SRPT analysis on boothcheck